| 4 Stocks With Impressive Interest Coverage Ratio to Buy Now |
STRL, AXS, MOH & HALO's impressive interest coverage ratios highlight that these companies can withstand financial hardships. |
zacks.com |
2025-05-14 16:26:16 |
Czytaj oryginał (ang.) |
| Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy? |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-05-13 14:50:48 |
Czytaj oryginał (ang.) |
| 3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) |
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes. |
zacks.com |
2025-05-12 17:50:47 |
Czytaj oryginał (ang.) |
| Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-05-12 14:45:55 |
Czytaj oryginał (ang.) |
| Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat |
Halozyme Therapeutics reported strong Q1 2025 earnings with a 35% revenue increase, 54% net income growth, and raised full-year guidance, reinforcing its status as a top biotech growth story. Key growth drivers include the ENHANZE portfolio with new blockbuster drugs, a robust clinical pipeline, and next-gen delivery systems, ensuring sustained royalty growth and competitive advantage. Despite potential risks like the Keytruda SC litigation and pharma tariffs, Halozyme's strong balance sheet, rising free cash flow, and share buybacks boost EPS and shareholder value. |
seekingalpha.com |
2025-05-12 14:44:40 |
Czytaj oryginał (ang.) |
| S&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy Points |
Visa has topped a buy point, while fellow S&P 500 component Insulet gapped out of a base, leading five stocks on this weekend watchlist. |
investors.com |
2025-05-10 15:47:52 |
Czytaj oryginał (ang.) |
| Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy? |
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2025-05-09 17:00:51 |
Czytaj oryginał (ang.) |
| Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-05-08 14:55:57 |
Czytaj oryginał (ang.) |
| HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View |
Halozyme reports better-than-expected first-quarter 2025 results. The company increases revenue guidance for 2025. |
zacks.com |
2025-05-07 17:15:38 |
Czytaj oryginał (ang.) |
| Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates |
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-05-07 00:00:46 |
Czytaj oryginał (ang.) |
| Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript |
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communications Helen Torley - President & Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Sadia Rahman - Wells Fargo Sean Laaman - Morgan Stanley Michael DiFiore - Evercore ISI Mitchell Kapoor - H.C. Wainwright Brendan Smith - TD Cowen David Risinger - Leerink Partners Operator Good afternoon. |
seekingalpha.com |
2025-05-06 23:15:27 |
Czytaj oryginał (ang.) |
| Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates |
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.11 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.79 per share a year ago. |
zacks.com |
2025-05-06 22:35:33 |
Czytaj oryginał (ang.) |
| HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS |
Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; Adjusted EBITDA Increased 40% YOY to $162 million; GAAP Diluted EPS Increased 55% YOY to $0.93; non-GAAP Diluted EPS Increased 41% YOY to $1.11 1 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,200 - $1,280 million, Representing YOY Growth of 18% - 26%, Adjusted EBITDA to $790 - $840 million, Representing YOY Growth of 25% - 33% and non-GAAP Diluted EPS to $5.30 - $5.70, Representing YOY Growth of 25% - 35%1 SAN DIEGO , May 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the first quarter ended March 31, 2025, provided an update on its recent corporate activities and raised its 2025 financial guidance. "2025 is off to a strong start with our current three blockbuster brands, Darzalex SC, Phesgo and VYVGART Hytrulo, continuing to demonstrate strong growth in their currently approved indications. |
prnewswire.com |
2025-05-06 20:01:00 |
Czytaj oryginał (ang.) |
| Halozyme to Participate in the BofA Securities 2025 Healthcare Conference |
SAN DIEGO , May 5, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the BofA Securities 2025 Healthcare Conference. The presentation is scheduled for Tuesday, May 13 at 4:20pm PT / 7:20pm ET. |
prnewswire.com |
2025-05-05 21:15:00 |
Czytaj oryginał (ang.) |
| Halozyme Therapeutics: Still Undervalued Ahead Of Earnings |
Halozyme Therapeutics, Inc. remains a buy due to its strong subscription-based business model, high growth, and undervaluation. HALO's robust product library, focused on drug delivery systems, positions it well to avoid sector issues and continue outperforming the market. The company has shown consistent revenue growth, high gross margins, and strong returns on investments, with a fair value estimated at $67.71. |
seekingalpha.com |
2025-05-01 13:06:24 |
Czytaj oryginał (ang.) |
| Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? |
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-29 15:06:21 |
Czytaj oryginał (ang.) |
| Halozyme to Report First Quarter 2025 Financial and Operating Results |
SAN DIEGO , April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, May 6, 2025 at 1:30 p.m. |
prnewswire.com |
2025-04-28 12:30:00 |
Czytaj oryginał (ang.) |
| Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
European Commission (EC) decision on marketing authorization application expected within approximately two months SAN DIEGO , April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20) for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. The SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional. |
prnewswire.com |
2025-04-28 11:30:00 |
Czytaj oryginał (ang.) |
| Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation |
Complaint filed in New Jersey alleges Merck uses Halozyme's patented MDASE technology to develop SC Keytruda Halozyme is seeking damages and injunctive relief to stop the infringement SAN DIEGO , April 24, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase for subcutaneous drug delivery, today filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. (Merck) in U.S. District Court in New Jersey. Halozyme believes the subcutaneous formulation of Merck's cancer medicine, Keytruda, infringes multiple patents that Halozyme filed beginning in 2011 to protect its groundbreaking MDASE subcutaneous delivery technology. |
prnewswire.com |
2025-04-24 12:30:00 |
Czytaj oryginał (ang.) |
| Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management |
AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™ AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™ |
globenewswire.com |
2025-04-23 13:15:00 |
Czytaj oryginał (ang.) |
| Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference |
SAN DIEGO , Feb. 26, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the TD Cowen 45th Annual Healthcare Conference. The presentation is scheduled for Wednesday, March 5 at 8:50am PT / 11:50am ET. |
prnewswire.com |
2025-02-26 10:30:00 |
Czytaj oryginał (ang.) |
| Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes" |
Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market. |
zacks.com |
2025-02-24 15:45:31 |
Czytaj oryginał (ang.) |
| Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-02-20 12:50:27 |
Czytaj oryginał (ang.) |
| HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth |
Halozyme reports better-than-expected fourth-quarter 2024 results. The company maintains revenue guidance for 2025. |
zacks.com |
2025-02-19 12:20:23 |
Czytaj oryginał (ang.) |
| Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript |
Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript |
seekingalpha.com |
2025-02-18 21:55:17 |
Czytaj oryginał (ang.) |
| Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-02-18 20:31:13 |
Czytaj oryginał (ang.) |
| Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates |
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $0.82 per share a year ago. |
zacks.com |
2025-02-18 20:16:10 |
Czytaj oryginał (ang.) |
| HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS |
Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 million Fourth Quarter Net Income Increased 60% YOY to $137 million; Adjusted EBITDA Increased 61% YOY to $196 million; GAAP EPS Increased 63% YOY to $1.06; non-GAAP EPS Increased 54% YOY to $1.26 1 Record Full Year 2024 Total Revenue Increased 22% YOY to $1,015 million and Record Royalty Revenue Exceeded Guidance Increasing 27% YOY to $571 million Full Year 2024 Net Income Increased 58% YOY to $444 million; GAAP EPS Increased 63% YOY to $3.43; Adjusted EBITDA Increased 48% YOY to $632 million and non-GAAP EPS Increased 53% YOY to $4.23 1 , Both Exceeding Guidance Reiterating 2025 Financial Guidance Ranges for Total Revenue of $1,150 - 1,225 million, Representing YOY Growth of 13% - 21%, Adjusted EBITDA of $755 - $805 million, Representing YOY Growth of 19% - 27% and non-GAAP Diluted EPS of $4.95 - $5.35, Representing YOY Growth of 17% - 26%1 SAN DIEGO , Feb. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the fourth quarter and full year ended December 31, 2024, provided an update on its recent corporate activities and reiterated its 2025 financial guidance. "I am excited to announce that the significant growth we achieved throughout the year culminated in two important milestones for the Company: achievement of more than $1 billion in total revenue and reaching a cumulative one million patients with our ENHANZE drug delivery technology. |
prnewswire.com |
2025-02-18 18:01:00 |
Czytaj oryginał (ang.) |
| Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment |
HOUSTON, TX, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces that it has received Institutional Review Board (IRB) approval from the University of California, San Diego (UCSD) for clinical testing of its HALO™ Clarity (HALO) headset in human subjects. This study is being conducted independently by UCSD. |
globenewswire.com |
2025-02-18 10:30:00 |
Czytaj oryginał (ang.) |
| Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-02-17 12:46:32 |
Czytaj oryginał (ang.) |
| Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast? |
Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week. |
zacks.com |
2025-02-17 12:30:34 |
Czytaj oryginał (ang.) |
| HALO Gears Up to Report Q4 Earnings: Here's What You Should Know |
Halozyme's fourth-quarter earnings are likely to have gained from higher royalty payments and revenues from collaboration agreements for its Enhanze technology. |
zacks.com |
2025-02-13 14:06:08 |
Czytaj oryginał (ang.) |
| Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-02-13 12:46:13 |
Czytaj oryginał (ang.) |
| Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results |
SAN DIEGO , Feb. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 financial and operating results on Tuesday, February 18, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, February 18, 2025 at 1:30 p.m. |
prnewswire.com |
2025-02-04 10:30:00 |
Czytaj oryginał (ang.) |
| CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer |
SAN DIEGO , Feb. 3, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending an extension of marketing authorisation for a subcutaneous (SC) formulation of RYBREVANT® (amivantamab) in combination with LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, and as a monotherapy for the treatment of adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations after failure of platinum-based therapy. "We are pleased that the subcutaneous formulation of amivantamab, which was developed with our ENHANZE drug delivery technology, was recommended for approval in Europe," said Dr. Helen Torley, president and chief executive officer of Halozyme. |
prnewswire.com |
2025-02-03 09:30:00 |
Czytaj oryginał (ang.) |
| Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-01-31 12:40:21 |
Czytaj oryginał (ang.) |
| Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-01-28 12:46:07 |
Czytaj oryginał (ang.) |
| Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-01-27 12:56:28 |
Czytaj oryginał (ang.) |
| 5 Biotech Stocks Worth Adding to Your Portfolio in 2025 |
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector. |
zacks.com |
2025-01-14 13:06:12 |
Czytaj oryginał (ang.) |
| Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why |
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes. |
zacks.com |
2025-01-10 15:45:22 |
Czytaj oryginał (ang.) |
| Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025 |
Halozyme Therapeutics, Inc.'s subcu drug delivery business, driven by ENHANZE technology, shows strong revenue growth with significant collaborations, but faces potential challenges post-2030 due to expiring licensing agreements. The failed $2.1bn Evotec acquisition, while initially promising, may have been a blessing in disguise for HALO given Evotec's uncertain and loss-making business model. Recent approvals, including subcutaneous Opdivo (Qvantiq) and other products, e.g. Roche's Ocrevus, suggest a positive outlook for 2025, potentially boosting Halozyme's share price. |
seekingalpha.com |
2025-01-03 17:42:28 |
Czytaj oryginał (ang.) |
| Halozyme: Recent Approvals Alter My Appetite |
Halozyme's attempt to acquire Evotec was a bold move to diversify revenue but was ultimately unsuccessful, impacting HALO's stock price. Despite a CRL for Rybrevant, Halozyme's technology saw success with FDA approval of Opdivo Qvantig, promising future royalty revenue. Halozyme's strong clinical track record and projected 20% CAGR in royalty revenue position it for significant growth through 2028. |
seekingalpha.com |
2024-12-31 04:41:19 |
Czytaj oryginał (ang.) |
| Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia |
SAN DIEGO , Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Takeda received regulatory approval for HYQVIA® [Immune Globulin Infusion 10% (Human) with Halozyme's Recombinant Human Hyaluronidase] by the Japanese Ministry of Health, Labour and Welfare (MHLW) for patients with agammaglobulinemia or hypogammaglobulinemia, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immunodeficiency (SID). HYQVIA® is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20), which is Halozyme's ENHANZE® drug delivery technology. |
prnewswire.com |
2024-12-30 09:00:00 |
Czytaj oryginał (ang.) |
| Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy |
SAN DIEGO , Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated with Halozyme's ENHANZE® drug delivery technology, was granted regulatory approval by Japan's Ministry of Health, Labour and Welfare (MHLW) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVDURA was approved for CIDP as a once weekly 30-to-90 second subcutaneous injection, which can be self-administered at home, and is the first and only neonatal Fc receptor (FcRn) blocker approved for the treatment of CIDP. |
prnewswire.com |
2024-12-30 08:45:00 |
Czytaj oryginał (ang.) |
| Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications |
Opdivo Qvantig represents the first and only subcutaneously administered PD-1 inhibitor Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to IV Opdivo in the Phase 3 CheckMate-67T trial SAN DIEGO , Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval for Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) co-formulated with Halozyme's ENHANZE® drug delivery technology for subcutaneous use in most previously approved adult, solid tumor intravenous (IV) Opdivo® indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy® (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib. Opdivo Qvantig is the first and only subcutaneously administered PD-1 inhibitor. |
prnewswire.com |
2024-12-30 08:30:00 |
Czytaj oryginał (ang.) |
| 3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) |
Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
zacks.com |
2024-12-23 15:46:08 |
Czytaj oryginał (ang.) |
| HALO or FOLD: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2024-12-23 14:46:21 |
Czytaj oryginał (ang.) |
| How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08% |
The average of price targets set by Wall Street analysts indicates a potential upside of 27.1% in Halozyme Therapeutics (HALO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-12-16 12:57:22 |
Czytaj oryginał (ang.) |
| Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-12-11 12:46:36 |
Czytaj oryginał (ang.) |
| Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-12-09 12:50:28 |
Czytaj oryginał (ang.) |
| Is Halozyme Therapeutics (HALO) Stock Undervalued Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-12-09 12:46:33 |
Czytaj oryginał (ang.) |
| Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now |
Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market. |
zacks.com |
2024-12-05 15:46:09 |
Czytaj oryginał (ang.) |
| HALO vs. FOLD: Which Stock Is the Better Value Option? |
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two stocks is more attractive to value investors? |
zacks.com |
2024-12-05 14:41:25 |
Czytaj oryginał (ang.) |
| Is Halozyme Therapeutics (HALO) Outperforming Other Medical Stocks This Year? |
Here is how Halozyme Therapeutics (HALO) and Addus HomeCare (ADUS) have performed compared to their sector so far this year. |
zacks.com |
2024-12-05 12:45:42 |
Czytaj oryginał (ang.) |
| Halozyme to Present at Upcoming Investor Conferences |
SAN DIEGO , Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the executive leadership team are scheduled to present and host investor meetings at the following investor conferences. Details on the presentations are as follows: Event: Piper Sandler 36th Annual Healthcare Conference Presenter: Nicole LaBrosse, Chief Financial Officer Format: Fireside Chat and 1x1 Meetings Presentation Date: Wednesday, December 4, 2024 Presentation Time: 10:30am PT / 1:30pm ET Location: New York, NY Event: 7th Annual Evercore ISI HealthCONx Conference Presenter: Helen Torley, President and Chief Executive Officer Format: Fireside Chat and 1x1 Meetings Presentation Date: Wednesday, December 4, 2024 Presentation Time: 9:30am PT / 12:30pm ET Location: Miami, FL A live audio webcast of the presentations will be available in the Investor Relations section of the Company's website. |
prnewswire.com |
2024-11-27 10:30:00 |
Czytaj oryginał (ang.) |
| HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up |
Halozyme withdraws its proposal to acquire Evotec for 11 euro per share in cash. The company maintains its 2024 revenue guidance. |
zacks.com |
2024-11-25 13:40:30 |
Czytaj oryginał (ang.) |
| Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why |
Halozyme Therapeutics (HALO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-11-22 15:05:22 |
Czytaj oryginał (ang.) |
| Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-11-22 12:45:39 |
Czytaj oryginał (ang.) |
| Halozyme withdraws $2.1 bln buyout offer for Evotec |
Halozyme Therapeutics said on Friday it had withdrawn its proposal to acquire Evotec SE for 2 billion euros ($2.09 billion) after the German drug developer was unwilling to engage in discussions. |
reuters.com |
2024-11-22 10:55:45 |
Czytaj oryginał (ang.) |
| Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions |
SAN DIEGO , Nov. 22, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. Helen Torley, president and chief executive officer of Halozyme , shared the following statement: "We continue to believe that a combination of Halozyme and Evotec would create a leading, differentiated, global pharma services company, benefitting shareholders, patients and employees. |
prnewswire.com |
2024-11-22 10:35:00 |
Czytaj oryginał (ang.) |